Arcutis Biotherapeutics – 59% Growth and ZORYVE Market Share Gains
Reading Time: 3 minutes
With ZORYVE, Arcutis treats chronic skin diseases without corticosteroids and gains market share. New pediatric approvals and study data open up additional patient groups and markets. In the second quarter, product sales increased by 59%. Arcutis returns to profitability. Arcutis Biotherapeutics (ARQT) is developing into a profitable growth company with one approved product to date. The driver is ZORYVE, a corticosteroid-free medication for chronic skin conditions. The anti-inflammatory agent Roflumilast is applied once daily as a cream...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
